Reblozyl (luspatercept–aamt)

Thanks to Celgene, Bristol Myers' thinks its late-stage pipeline will rake in $20 billion in yearly sales starting in 2025, up from $15 billion.

Amirah Al Idrus Jun 25, 2020 11:45am

Jan 27, 2020 5:42pm